NEW YORK (GenomeWeb News) — Sequenom today said that New York State health officials have approved a noninvasive prenatal test based on the firm’s SEQureDx technology for cell-free fetal nucleic-acid assessment.
 
The lab-developed test, performed on a real-time PCR platform, is designed to detect Rhesus D incompatibility. It will be marketed by Lenetix Medical Screening Laboratory, Sequenom’s CLIA-certified, nonexclusive licensee.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers describe a way to share data while keeping it secure, Agence France Presse reports.

In Science this week: genetic mutations typically associated with esophageal cancer are common in older, healthy individuals, and more.

India's Council of Scientific and Industrial Research has a new director-general, according to ScienceInsider.

A new study links more than a hundred genes to autism spectrum disorder, Discover's D-brief blog reports.